The OSUCCC Analytical Cytometry Shared Resource (ACSR) is an extensive, institutionally-supported shared service. This core provides one of the only means of rapidly and accurately analyzing multiple characteristics of biological particles while also being able to rapidly, accurately, and with high purity (>98%) sort out pure populations of cells of interest based on parameters designated by the investigator. Furthermore, this service provides OSUCCC members with the ability to obtain viable, sterile and pure populations of cells so that they may be individually cloned, can be assessed for immunological function, or can be examined for specific biochemical properties with minimal manipulations, compared to magnetic bead technologies. This shared resource has five primary goals: 1) Provide state of the art flow cytometry analysis and sorting on a fee-for-service basis;2) Provide individual training followed by 24-hour access to flow cytometry instrumentation for researchers who wish to conduct their own analysis;3) Develop and provide educational and training opportunities for new and experienced resource users as well as forums to introduce new instrumentation, technologies and reagents to OSUCCC investigators;4) Obtain and provide state-of-the-art equipment to support high quality cancer research for OSUCCC members;and 5) Introduce new, or pre-commercial, emerging technology to support high quality cancer research for OSUCCC members. The ACSR main facility is centrally located and has eight flow cytometry instruments, four of which are capable of sorting. Two flow cytometer analyzers are available for independent (24 hour access) and assisted analysis. In addition, commercial and prototype magnetic separation and analysis equipment is available. Five'of these instruments were purchased with institufional support of approximately $1,358,000 in the last four years. In order to meet the needs of heavy users and maintain adequate space and access, the ACSR has two satellite facilifies located in the James Cancer Hospital (JCH) and the OSU College of Veterinary Medicine (CVM). The CVM has three flow cytometers, one of which is equipped to safely sort virus infected cells. The ACSR Director is Jeffrey Chalmers, Ph.D. with a manager, Bryan McElwain, and two additional staff. The CVM satellite is managed by A. Nicole White and has an additional technician. In addition, this past year Mary Jo Burkhard, D.V.M., Ph.D. was recruited as a co-investigator in the ACSR focused on education and outreach. The ACSR continues to provide critical support to the investigators and scientific programs, including 14 clinical studies acfively using the services of the ACSR This past year, nearly 75% of the ACSR usage was from 63 CCSG peer-reviewed, funded OSUCCC investigators from all six programs who consumed over 4,300 hours of service, yet only 23.4% of the support came from the CCSG.

Public Health Relevance

The ACSR provides instrumentation and technical operation/support for cell identification, characterization and cell separation to OSUCCC members and the University community. The ACSR, through exceptional institutional support and experienced leadership, is designed to provide affordable and high quality service in each of these areas, based on a cost-effective charge-back system. This ACSR provides critical support to OSUCCC scientific programs and clinical studies, while contributing outstanding technical expertise to high quality scientific cancer research.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016058-37
Application #
8567275
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2012-12-01
Budget End
2013-11-30
Support Year
37
Fiscal Year
2013
Total Cost
$98,325
Indirect Cost
$33,851
Name
Ohio State University
Department
Type
DUNS #
832127323
City
Columbus
State
OH
Country
United States
Zip Code
43210
Salem, Galena; Ruppert, Amy S; Elder, Patrick et al. (2015) Lower dose of antithymocyte globulin does not increase graft-versus-host disease in patients undergoing reduced-intensity conditioning allogeneic hematopoietic stem cell transplant. Leuk Lymphoma 56:1058-65
Niederwieser, C; Kohlschmidt, J; Volinia, S et al. (2015) Prognostic and biologic significance of DNMT3B expression in older patients with cytogenetically normal primary acute myeloid leukemia. Leukemia 29:567-75
Billingsley, Caroline C; Cohn, David E; Mutch, David G et al. (2015) Polymerase ? (POLE) mutations in endometrial cancer: clinical outcomes and implications for Lynch syndrome testing. Cancer 121:386-94
Krok-Schoen, Jessica L; Kurta, Michelle L; Weier, Rory C et al. (2015) Clinic type and patient characteristics affecting time to resolution after an abnormal cancer-screening exam. Cancer Epidemiol Biomarkers Prev 24:162-8
Biddle, Martha J; Lennie, Terry A; Bricker, Gregory V et al. (2015) Lycopene dietary intervention: a pilot study in patients with heart failure. J Cardiovasc Nurs 30:205-12
Jin, Ming; Roth, Rachel; Rock, Jonathan B et al. (2015) The impact of tumor deposits on colonic adenocarcinoma AJCC TNM staging and outcome. Am J Surg Pathol 39:109-15
Llanos, Adana A; Pennell, Michael L; Young, Gregory S et al. (2015) No association between colorectal cancer worry and screening uptake in Appalachian Ohio. J Public Health (Oxf) 37:322-7
Nguyen, Huyen T; Jia, Guang; Shah, Zarine K et al. (2015) Prediction of chemotherapeutic response in bladder cancer using K-means clustering of dynamic contrast-enhanced (DCE)-MRI pharmacokinetic parameters. J Magn Reson Imaging 41:1374-82
Berman-Booty, Lisa D; Thomas-Ahner, Jennifer M; Bolon, Brad et al. (2015) Extra-prostatic transgene-associated neoplastic lesions in transgenic adenocarcinoma of the mouse prostate (TRAMP) mice. Toxicol Pathol 43:186-97
Pant, Shubham; Martin, Ludmila K; Geyer, Susan et al. (2014) Baseline serum albumin is a predictive biomarker for patients with advanced pancreatic cancer treated with bevacizumab: a pooled analysis of 7 prospective trials of gemcitabine-based therapy with or without bevacizumab. Cancer 120:1780-6

Showing the most recent 10 out of 1178 publications